Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||43.07%||Sales Growth - Q/Q||27.68%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-80.97%||ROE||156.1%||ROI||-102.16%|
|Current Ratio||2.13||Quick Ratio||2.09||Long Term Debt/Equity||5.49||Debt Ratio||-0.4|
|Gross Margin||91.55%||Operating Margin||-615.77%||Net Profit Margin||-774.12%||Dividend Payout Ratio|
|Cash From Financing Activities||-220 K||Cash From Investing Activities||49.9 M||Cash From Operating Activities||-45.09 M||Gross Profit||8.62 M|
|Net Profit||-35.17 M||Operating Profit||-22.76 M||Total Assets||282.93 M||Total Current Assets||125.04 M|
|Total Current Liabilities||58.68 M||Total Debt||368.43 M||Total Liabilities||429.69 M||Total Revenue||9.39 M|
|High 52 week||31.36||Low 52 week||13.65||Last close||22.78||Last change||-1.85%|
|RSI||36.29||Average true range||0.77||Beta||1.53||Volume||4.05 M|
|Simple moving average 20 days||-1.57%||Simple moving average 50 days||7.48%||Simple moving average 200 days||16.09%|
|Performance Week||-1.51%||Performance Month||9.89%||Performance Quart||52.37%||Performance Half||10.48%|
|Performance Year||-24.62%||Performance Year-to-date||15.81%||Volatility daily||2.78%||Volatility weekly||6.22%|
|Volatility monthly||12.74%||Volatility yearly||44.13%||Relative Volume||263.48%||Average Volume||4.4 M|
|New High||New Low|
2019-03-18 14:26:28 | Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'
2019-03-18 13:06:50 | Signal Says Buy Options Insurance on This Biotech
2019-03-14 17:50:09 | Exelixis EXEL Gains As Market Dips: What You Should Know
2019-03-14 17:00:25 | How a biotech company navigated bay bureaucracy to set up a commuter ferry service
2019-03-14 09:30:01 | Why Is Exelixis EXEL Up 12.1% Since Last Earnings Report?
2019-03-13 17:31:31 | 5 Biotech Stocks to Keep an Eye on in 2019
2019-03-13 13:21:01 | Why Exelixis, Inc. NASDAQ:EXEL Is An Attractive Investment To Consider
2019-03-12 10:01:02 | Pfizer's PFE Kidney Cancer Drug Combo Gets EMA's Validation
2019-03-08 17:50:10 | Exelixis EXEL Dips More Than Broader Markets: What You Should Know
2019-03-05 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in March
2019-03-05 07:15:00 | 3 Best Biotech Bargain Stocks on the Market Right Now
2019-02-22 16:48:42 | Exelixis Inc EXEL Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-19 07:17:00 | Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
2019-02-15 06:52:11 | New Strong Sell Stocks for February 15th
2019-02-14 08:40:01 | Implied Volatility Surging for Exelixis EXEL Stock Options
2019-02-13 18:51:33 | Cramer's lightning round: These are the two pot stocks I'm recommending
2019-02-13 15:47:00 | Exelixis Grabs 90% of First Place
2019-02-13 13:25:06 | Exelixis EXEL Earnings, Revenues Beat Estimates in Q4
2019-02-13 09:35:00 | Exelixis Rises as Fourth-Quarter Earnings Beat Estimates
2019-02-13 09:08:00 | These 'Small Ball' Names Will Outperform the Market in 2019
2019-02-13 03:29:53 | Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT
2019-02-12 23:08:54 | Exelixis, Inc EXEL Q4 2018 Earnings Conference Call Transcript
2019-02-12 17:47:22 | Exelixis: 4Q Earnings Snapshot
2019-02-12 17:20:10 | Exelixis EXEL Tops Q4 Earnings and Revenue Estimates
2019-02-12 15:00:00 | Exelixis, Inc. to Host Earnings Call
2019-02-12 08:16:04 | Q4 Earnings Preview For Exelixis
2019-02-12 08:04:55 | The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
2019-02-10 17:37:42 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
2019-02-08 08:06:45 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-02-07 16:31:09 | Exelixis EXEL to Report Q4 Earnings: What's in Store?
2019-02-06 10:29:54 | Here’s What Exelixis, Inc.’s NASDAQ:EXEL P/E Ratio Is Telling Us
2019-02-05 10:30:03 | Exelixis EXEL Earnings Expected to Grow: Should You Buy?
2019-02-01 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics — New Research Emphasizes Economic Growth
2019-01-22 08:07:03 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-01-18 17:45:10 | Exelixis EXEL Stock Sinks As Market Gains: What You Should Know
2019-01-17 10:18:03 | Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave
2019-01-15 08:49:01 | Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
2019-01-15 08:06:37 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-01-15 07:50:00 | Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine
2019-01-14 18:05:11 | 5 Reasons Why Investors Should Buy Exelixis EXEL in 2019
2019-01-14 17:48:00 | Exelixis stock up more than 4% after FDA drug approval
2019-01-13 15:50:01 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials